{"filings":[{"id":2105812,"accession_number":"0001604821-26-000015","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2026-08-06T20:05:21+00:00","items":["2.02","9.01"],"status":"ready","headline":"Natera Q2 revenue $752.8M (+37.7% YoY); raises FY2026 guidance by $100M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $752.8M (+37.7% YoY); tests processed 1,043,900 (+22.4%); oncology tests 296,700 (+57.2%).","Net loss $67.0M ($0.47 diluted EPS) vs $100.9M ($0.74) in Q2 2025; operating loss $75.8M vs $110.4M.","Raised 2026 annual revenue guidance by $100M midpoint to $2.85B-$2.91B; gross margin ~64-66%.","Cash increased $3.6M in Q2 to $1,091.5M; debt $80.3M under UBS line at SOFR+50bps.","CEO cites Signatera regulatory approvals, Medicare coverage for Prospera, and Panorama NIPT launch."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1471397,"accession_number":"0001604821-26-000005","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2026-07-06T20:05:18+00:00","items":["5.02"],"status":"ready","headline":"Director Monica Bertagnolli resigns from Natera board for new role at National Academy of Medicine","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Resignation effective July 1, 2026, due to new position with the National Academy of Medicine.","Bertagnolli served on the Board and its committees; departure not due to any disagreement with Natera.","No replacement named; board size and composition impact not disclosed.","Resignation is a routine director change for external professional opportunity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1083837,"accession_number":"0001604821-26-000004","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K/A","filed_at":"2026-06-16T20:08:11+00:00","items":["5.02","9.01"],"status":"ready","headline":"Natera appoints Thomas Lynch to Board, expanding to 12 directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from 11 to 12 members; Lynch appointed effective June 2, 2026.","Lynch will serve as Class I director with term expiring at 2028 annual meeting.","Appointed to Human Capital Committee; determined independent under Nasdaq rules.","Will receive cash and equity per non-employee director compensation plan (referenced filings).","No family relationships or material interests with Natera officers or directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1083838,"accession_number":"0001604821-26-000003","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2026-06-16T20:06:47+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Natera stockholders approve 3.2M share increase to 2015 equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2015 Equity Incentive Plan, adding 3.2M common shares.","Four directors elected: Rowan Chapman, Herm Rosenman, Jonathan Sheena (Class II), and Eric H. Rubin (Class I).","Ernst & Young ratified as independent auditor for FY2026 with 129.8M votes for.","Say-on-pay proposal approved with 119.9M votes for; frequency set at one year.","All proposals passed; quorum of 130.7M shares present."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":888276,"accession_number":"0001604821-26-000002","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2026-06-05T20:08:09+00:00","items":["5.02","9.01"],"status":"ready","headline":"Natera appoints Thomas Lynch to board, expands board to 12","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thomas Lynch appointed as Class I director effective June 2, 2026; term expires at 2028 annual meeting.","Board size increased from 11 to 12; Lynch deemed independent, serves on Human Capital Committee.","Compensated per non-employee director program; initial equity award vests one-third annually over three years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94036,"accession_number":"0001628280-26-032101","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Natera Q1 revenue $696.6M (+39% YoY); raises FY2026 guidance by $120M to $2.78B midpt","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $696.6M (+38.8% YoY); tests processed 1,013,600 (+18.5%), oncology tests up 54.4%.","Net loss $85.1M ($0.60/sh) vs $66.9M ($0.50) prior year; positive cash inflow $11.8M.","Raises FY2026 revenue guidance by $120M midpoint to $2.74B-$2.82B; gross margin expected 64%-66%.","Operating expenses $538.6M (+36.0%) on headcount growth and clinical trial expenses.","Cash and equivalents $1,087.9M; debt $80.3M under line of credit."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":696644000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94035,"accession_number":"0001104659-26-038519","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Natera appoints Eric Rubin to Board, increasing size to 11","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric Rubin appointed as independent Class I director effective March 26, 2026; term expires at 2028 annual meeting.","Board size increased from 10 to 11 members; Rubin joins the Nominating, Corporate Governance and Compliance Committee.","Initial equity award vests in three equal installments on March 26, 2027, 2028, and 2029.","Standard non-employee director cash and equity compensation; indemnification agreement entered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106104,"accession_number":"0001104659-26-020482","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Natera Q4 2025 revenue $665.5M (+39.8% YoY); guides FY26 revenue $2.62-2.70B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $665.5M Q4 2025 vs $476.1M Q4 2024 (+39.8%); FY2025 revenue $2,306.1M (+35.9%).","Gross margin 66.9% Q4 2025 vs 62.9% Q4 2024; FY2025 gross margin 64.7%.","Oncology test volumes up 54.7% YoY in Q4 (233,300 tests) and 51.6% for FY2025.","Full-year positive cash inflow of $107.6M; net loss $208.2M ($1.52 per diluted share).","FY2026 guidance: revenue $2.62-2.70B, gross margin ~63-65%, positive cash inflow."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":2306113000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106103,"accession_number":"0001104659-26-002861","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Natera preliminary Q4 rev ~$660M (+39% YoY), FY rev ~$2.3B (+35%), above outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue ~$660M (+39% YoY); FY 2025 ~$2.3B (+35%), ~$40M above top end of prior outlook.","Oncology tests Q4: 233,300 total (225,300 clinical MRD), up 55% YoY; record sequential growth of ~22,800 MRD tests.","Total tests processed Q4: 923,600 (+17% YoY); FY: 3,525,500 (+15%).","Cash inflows Q4 ~$30M; FY >$100M, driven by operational improvements."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":2306113000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122393,"accession_number":"0001104659-25-118664","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Natera acquires Foresight Diagnostics for $275M upfront plus $175M earnouts","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["All-stock acquisition includes $275M upfront consideration plus up to $175M in revenue- and reimbursement-based milestone earnouts.","Adds Foresight's PhasED-Seq phased variant technology with LOD95 of 0.3 ppm, enhancing Signatera MRD platform.","Expands Natera's presence in lymphoma, with Foresight's CLARITY MRD assay used in three prospective trials and NCCN guideline inclusion.","Integration of phased variants into Signatera platform expected to be launched for clinical use in 2026.","Company issued 1,127,982 shares upfront and up to ~824,583 additional contingent shares; will file registration for resale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122392,"accession_number":"0001104659-25-107727","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Natera Q3 revenue up 35% to $592M; raises FY2025 guidance by $160M midpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $592.2M (+34.7% YoY); product rev +35.3%; gross margin 64.9% vs 61.8%.","Oncology tests 211,000 (+53.9% YoY); record MRD sequential growth of ~21,500 units.","Positive cash flow $26.4M in Q3; net loss $(0.64)/share vs $(0.26) YoY.","Raises FY2025 revenue guidance to $2.18B-2.26B from $2.02B-2.10B.","FY2025 guidance: gross margin ~62-64%; net cash inflow ~$100M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":1640615000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139100,"accession_number":"0001104659-25-075189","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Natera Q2 revenue up 32% to $546.6M; raises FY2025 revenue outlook by $80M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $546.6M (+32.2% YoY); product revenue $544.4M (+32.3%).","Oncology tests grew 50.6% to 188,800; total tests processed 853,100 (+12.2%).","Achieved positive cash flow of ~$24.3M in Q2; cash and investments $1,016M.","Net loss per diluted share ($0.74) vs ($0.30) in Q2 2024, impacted by $19.8M legal accruals.","Raising 2025 revenue guidance to $2.02B-$2.10B from $1.94B-$2.02B; OpEx outlook unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":1048431000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156613,"accession_number":"0001104659-25-060626","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Natera stockholders approve 3.6M share equity plan increase and reelect three directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Directors Baynes, Marcus, and Williams-Brinkley reelected with 91.0M, 79.7M, and 109.0M votes for, respectively.","Ernst & Young ratified as auditor for FY2025: 116.8M for, 0.7M against.","Advisory vote on named executive officer compensation passed: 107.8M for, 4.6M against.","Amendment to 2015 Equity Incentive Plan adding 3.6M shares approved: 83.3M for, 29.1M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156612,"accession_number":"0001104659-25-046121","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Natera Q1 revenue $501.8M (+36.5% YoY); positive cash flow $23.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $501.8M (+36.5% YoY); product revenue $500.0M (+37.1%).","Gross margin 63.1% (up from 56.7%); tests processed 855,100 (+16.2%).","Net loss $66.9M ($0.50 EPS) improved from $67.6M ($0.56) in prior year.","Positive operating cash flow $23.2M; cash & investments $991.6M.","Oncology test volume 167,700 (+46.1% YoY); CEO cites record Signatera growth."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":501830000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175036,"accession_number":"0001104659-25-022968","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Natera appoints Monica Bertagnolli to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from 10 to 11; Bertagnolli appointed as Class III director, term expiring at 2027 annual meeting.","She previously served from Nov 2020 to Aug 2022 before becoming Director of the National Cancer Institute.","She is independent and appointed to Nominating, Corporate Governance and Compliance Committee.","Compensation consistent with other non-employee directors; initial equity award vests over three years.","Indemnification agreement entered into with Bertagnolli."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175035,"accession_number":"0001104659-25-018223","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Natera Q4 revenue $476M (+53% YoY); guides 2025 revenue $1.87-1.95B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $476.1M (+53% YoY); product revenue $472.9M (+53.9%).","Q4 gross margin 62.9% vs 51.4% a year ago; FY2024 GM 60.3%.","Q4 net loss $53.8M ($0.41/share) vs $78.0M ($0.65) in Q4 2023; op loss $64.7M.","Oncology tests in Q4 150,800 (+54.7% YoY); total tests 792,800 (+26.5%).","FY2025 guidance: rev $1.87-1.95B; GM ~60-64%; positive net cash inflow."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":1696911000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175034,"accession_number":"0001104659-25-002846","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Natera FY2024 preliminary revenue ~$1.7B (+56% YoY), positive cash inflow $86.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue ~$472M (+52% YoY); FY2024 revenue ~$1.7B (+56% YoY), ~$53M above top end of guidance.","Positive non-GAAP cash inflow of $86.3M in FY2024 vs. outflow of $267.1M in FY2023.","Total tests processed in FY2024 ~3.06M (+22.8% YoY); Q4 oncology tests up 54.7% to ~150,800.","Clinical oncology tests in FY2024 ~498,300 (+63% YoY); Q4 sequential increase of ~14,800 tests.","Company to present additional updates at J.P. Morgan Healthcare Conference on Jan 15, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":1696911000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191997,"accession_number":"0001104659-24-126348","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2024-12-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Natera amends employment agreement for Executive Chairman Matthew Rabinowitz","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rabinowitz's base salary set at 50% of CEO's base salary, with annual cash bonus up to 85% of base salary.","Annual equity awards valued at 80% of CEO's annual equity grants, split between time-based and performance-based vesting.","Severance includes lump-sum cash of 12 months' base salary (18 months if within 12 months of change in control) plus COBRA premiums for 12 months (18 months for CIC).","Time-based equity accelerates upon involuntary termination: greater of 50% of unvested shares or 12 months forward vesting; full acceleration upon CIC.","Performance-based equity awards granted after effective date vest based on actual performance multiplied by service fraction plus 12 months; CIC triggers greater of actual or 100% achievement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191996,"accession_number":"0001104659-24-116777","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Natera Q3 revenue $439.8M (+64% YoY), beats guidance; raises FY2024 forecast","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $439.8M (+63.9% YoY); product revenue up 64.4%; gross margin 61.8% vs 45.1%.","Oncology tests 137,100 (+54.4%); total tests processed 775,800 (+23.9%).","Net loss narrowed to $31.6M ($0.26/sh) from $109M ($0.95/sh); positive cash flow $34.5M.","2024 guidance raised: revenue $1.61-1.64B, gross margin 58-61%, net cash inflow $50-75M.","Cash $922.3M; all convertible notes redeemed/converted on Oct 11, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":1220850000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208467,"accession_number":"0001104659-24-087273","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Natera Q2 revenue up 58% to $413.4M, loss narrows to $37.5M, guides higher","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $413.4M (+58.1% YoY); product revenue $411.4M (+59.3%); gross margin 58.8% vs 45.2%.","Net loss $37.5M ($0.30 loss per share) vs $110.8M ($0.97) YoY; operating loss $43.9M vs $112.4M.","Processed ~760,300 tests (+23.2%); oncology tests up 50.2% to ~125,400.","Achieved positive cash flow ~$3.3M; FY 2024 revenue guidance raised to $1.49-$1.52B.","Cash and investments $887.1M; outstanding debt $364.0M as of June 30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":781092000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208466,"accession_number":"0001104659-24-081215","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2024-07-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Natera to redeem all $287.5M of 2.25% Convertible Notes due 2027 on Oct 11","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Natera elects to redeem all $287.5M aggregate principal of its 2.25% Convertible Senior Notes due 2027.","Redemption date set for October 11, 2024; price is 100% of principal plus accrued interest to that date.","Trustee instructed to issue redemption notice to registered holders; optional redemption right exercised by company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226147,"accession_number":"0001104659-24-072800","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Natera shareholders approve amended equity plan adding 6M shares; director Botha reelected narrowly","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended 2015 Equity Incentive Plan approved with 85.9M for, 21.5M against; adds 6M shares, extends term 10 years, removes evergreen feature.","Director Roelof Botha reelected with 54.5M for, 53.0M withheld — a 50.7% majority vote.","Directors Chapman (106.5M for) and Rabinowitz (102.5M for) easily elected; auditor Ernst & Young ratified (114.3M for).","Advisory say-on-pay approved with 101.6M for, 5.9M against.","Total outstanding shares 123.2M; quorum 114.7M shares present."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226146,"accession_number":"0001104659-24-059333","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Natera Q1 revenue $367.7M (+52% YoY), net loss narrows to $0.56/share; achieves positive cash flow","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $367.7M (+52.1% YoY); product revenue up 53.4%; gross margin 56.7% vs 38.7%.","Net loss $67.6M ($0.56/share) vs $136.9M ($1.23/share) YoY; achieved ~$3M positive cash flow.","Processed ~735,800 tests (+17.5%); oncology tests ~114,800 (+61.7%).","Launched fetal RhD NIPT test; published key data in oncology and organ health.","FY 2024 guidance: revenue $1.42B-$1.45B; gross margin 53-55%; net cash ($25M)-$25M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":367741000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245226,"accession_number":"0001104659-24-028724","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Natera Q4 revenue up 43% to $311M; net loss narrows; guides 2024 rev $1.32-1.35B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $311.1M (+43.2% YoY); product revenue up 44.3% to $307.3M.","Net loss per share Q4 ($0.65) vs ($1.37) prior year; full year loss ($3.78) vs ($5.57).","Gross margin Q4 51.4% vs 41.4% YoY; full year 45.5% vs 44.4%.","Oncology tests Q4 up 52.3% to 97,500; FY up 73.5% to 340,700.","FY2024 guidance: revenue $1.32-1.35B; gross margin 50-53%; net cash consumption $50-75M."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":1082571000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245225,"accession_number":"0001104659-24-005384","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2024-01-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Natera acquires Invitae's prenatal and carrier screening assets for $10M upfront","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront cash payment of $10 million to Invitae for reproductive health assets.","Additional potential milestone payments of $42.5 million, including cash and litigation-related credits.","Invitae will transition its non-invasive prenatal screening and carrier screening customers to Natera.","Acquisition expands Natera's cfDNA testing reach; CEO Steve Chapman cites commitment to service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245224,"accession_number":"0001104659-24-002451","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2024-01-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Natera prelim Q4 revenue ~$300M (+38% YoY); FY23 ~$1.07B (+30%), $20M above guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue approx. $300M, up 38% from $217M in Q4 2022.","Full year 2023 revenue approx. $1.07B, up 30% from $820M in 2022.","2023 revenue expected to be ~$20M above top end of prior guidance.","Results are preliminary and unaudited; final earnings call in Feb 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":1082571000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262677,"accession_number":"0001104659-23-115735","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Natera Q3 revenue $268.3M (+27% YoY), raises FY2023 revenue and margin guidance, reduces cash burn","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $268.3M, up 27% YoY; product revenue $265.2M, up 33% YoY.","Processed ~626,000 tests (+21% YoY); oncology tests ~89,000 (+68% YoY) with 81,000 Signatera clinical units (+85%).","Net loss improved to $109.0M ($0.95/share) from $121.5M ($1.25/share) in Q3 2022.","Raises 2023 revenue guidance to $1.035B-$1.05B (from $1.015B-$1.035B); cash burn reduced to $260M-$280M (from $300M-$325M).","Cash, equivalents and investments $936.6M; total debt $363.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":771466000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279861,"accession_number":"0001104659-23-098990","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2023-09-07T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Natera prices $250M follow-on offering of 4.55M shares at $55; net proceeds ~$235.4M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 4,550,000 shares of common stock at $55.00 per share; underwriters granted 30-day option for 682,500 additional shares.","Expected net proceeds of approximately $235.4 million, or $270.8 million if overallotment fully exercised.","Offering expected to close September 11, 2023; joint book-running managers: Morgan Stanley, Goldman Sachs, Cowen, Piper Sandler.","Proceeds for general corporate purposes; offering made under automatically effective Form S-3 shelf registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279860,"accession_number":"0001104659-23-087265","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Natera Q2 revenue $261.4M (+31.9% YoY); net loss narrows; raises FY 2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $261.4M, up 31.9% YoY; product revenue $258.3M (+32.7%).","Net loss $110.8M ($0.97/shr) vs loss $145.2M ($1.50/shr) YoY; operating loss $112.4M.","Tests processed 617,200 (+23.5% YoY); oncology tests 83,500 (+88.9% YoY).","Raised FY 2023 revenue guidance to $1.015B-$1.035B vs prior $995M-$1.015B.","Won litigation: $19.35M damages from ArcherDX/Invitae; CareDx damages reduced to $0."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":503160000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298328,"accession_number":"0001104659-23-071619","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Natera shareholders elect directors, ratify auditor, approve say-on-pay at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Class II directors: Rowan Chapman (62.5M for, 30.9M withhold), Herm Rosenman (59.0M for, 34.4M withhold), Jonathan Sheena (57.0M for, 36.4M withhold).","Ratified Ernst & Young as FY2023 auditor with 104.9M for, 0.4M against, 0.05M abstain.","Advisory vote on executive compensation approved: 88.6M for, 4.7M against, 11.9M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298327,"accession_number":"0001104659-23-057710","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Natera Q1 revenue $241.8M (+24.5% YoY), raises 2023 revenue guidance to $995M-$1.015B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $241.8M (+24.5% YoY); product revenue $237.8M (+25.2% YoY).","Tests processed 626,200 (+28% YoY); oncology tests 71,000 (+102% YoY).","Net loss $136.9M ($1.23/share) vs $138.6M ($1.45) in prior year; loss per share improved.","Raised 2023 revenue guidance to $995M-$1.015B from prior $990M-$1.0B; gross margin guidance unchanged at 41%-44%.","Secured Medicare coverage for Prospera heart transplant test and first commercial coverage for Signatera (Blue Shield CA)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":241756000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298326,"accession_number":"0001104659-23-048356","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2023-04-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Natera extends Executive Chairman Rabinowitz's term to Jan 2025, $400k salary","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rabinowitz to serve as Executive Chairman through Jan 31, 2025; base salary $400K per year.","Eligible for annual cash bonus of 85% of salary in FY2023 and FY2024 based on performance goals.","Annual equity awards at 80% of CEO's award value for FY2023 and FY2024, subject to board approval.","Amendment removes single-trigger accelerated vesting in change of control, revises good reason definition.","Severance terms vary based on mutual agreement to extend beyond Jan 2025; potential 100% equity acceleration if no agreement and no Chairman offer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318572,"accession_number":"0001104659-23-031367","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Natera discloses no exposure to Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["No cash deposits or securities held at Silicon Valley Bank as of March 10, 2023.","Statement issued to inform investors amid SVB's receivership.","Company (NTRA) has no direct exposure to SVB failure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318571,"accession_number":"0001104659-23-026715","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Natera Q4 revenue $217.3M (+25.6% YoY); net loss $142.6M; guides 2023 rev $980M-$1B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $217.3M (+25.6% YoY); product revenue $212.9M (+28.2%); tests processed 559,700 (+27.6%).","Full-year 2022 revenue $820.2M (+31.1% YoY); net loss $547.8M ($5.57/diluted) vs $471.7M ($5.21) in 2021.","Oncology tests 196,000 in 2022 (+158% YoY); 40 peer-reviewed studies for Signatera published.","2023 guidance: revenue $980M-$1B; gross margin 41%-44%; net cash consumption $300M-$325M.","Appointed Ruth Williams-Brinkley to board effective March 2, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":820222000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318570,"accession_number":"0001104659-23-024599","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Natera appoints Ruth Williams-Brinkley to board, increasing size to 10","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 9 to 10 members; Williams-Brinkley appointed effective March 2, 2023.","Williams-Brinkley will serve as Class I director with term expiring at 2025 annual meeting.","She qualifies as independent under Nasdaq rules and joins the Compensation Committee.","Compensation follows standard non-employee director program; indemnification agreement entered.","No family relationships or material interests with Natera directors or officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336812,"accession_number":"0001104659-22-119581","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2022-11-16T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Natera prices $400M follow-on offering of 11.43M shares at $35/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 11,430,000 shares at $35.00 per share, with underwriters' option for 1,714,500 additional shares.","Expected net proceeds of ~$376.6M ($433.2M if full option exercised).","Offering expected to close November 18, 2022, subject to customary conditions.","Joint book-runners: Morgan Stanley, Cowen, SVB Securities; co-manager Baird.","Proceeds intended for general corporate purposes; no specific use disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336811,"accession_number":"0001104659-22-115934","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Natera Q3 revenue $210.6M (+33% YoY), raises FY22 guidance to $810M-$830M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $210.6M, up 33% YoY; test volumes 517,500 (+27% YoY).","Net loss $121.5M ($1.25/share) vs $151.3M ($1.63) in Q3 2021.","Gross margin 44.7% vs 48.5% YoY due to labor/overhead costs; 2022 guidance raised by $40M.","Oncology tests 53,000 (+153% YoY); Signatera pan-cancer contract with VA and Medicare IO monitoring set at $7,489.","Board completes investigation, finds short seller allegations of wrongdoing unfounded."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":602970000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354188,"accession_number":"0001104659-22-091194","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2022-08-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Monica Bertagnolli resigns from Natera board to lead National Cancer Institute","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Monica Bertagnolli resigned from the Board and all committees effective August 12, 2022.","Resignation due to her appointment as Director of the National Cancer Institute.","Not related to any disagreement with Natera's operations, policies, or practices.","No replacement director has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354187,"accession_number":"0001104659-22-086135","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Natera Q2 revenue up 40% to $198.2M; raises FY2022 guidance to $805M-$825M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $198.2M (+39.6% YoY); product revenue $194.6M (+39.3%).","Tests processed ~499,900, up 33% YoY; net loss $145.2M ($1.50/share) vs $116.0M ($1.32).","2022 revenue guidance raised to $805M-$825M; gross margin ~46%-48%.","Cash & investments $638.7M, down from $914.5M at Dec 31, 2021; net cash consumption expected $370M-$400M.","Selected for UnitedHealthcare Preferred Lab Network; Medicare coverage for Signatera in muscle invasive bladder cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":392333000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372095,"accession_number":"0001104659-22-067171","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2022-06-01T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Natera shareholders reelect directors, ratify auditor, approve say-on-pay with 48% opposition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class I directors elected: Baynes (52M for/24M withheld), Healy (29M for/47M withheld), Marcus (37M for/39M withheld).","Ratification of Ernst & Young as independent auditor for FY2022 passed with 85.8M for, 132K against.","Advisory vote on executive compensation approved with 39.6M for vs 36.9M against (51.8% of votes cast), indicating ~48% dissent.","All proposals passed; quorum of 86M shares present out of 96M outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372094,"accession_number":"0001104659-22-056451","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Natera Q1 revenue $194.1M (+27.5% YoY), raises 2022 guidance to $790-810M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $190M, up 57.8% YoY; processed 489,300 tests, up 40.5%.","Net loss $138.6M or ($1.45) per share vs. ($0.74) a year ago.","Raised 2022 revenue guidance from $770-790M to $790-810M.","Board and executives elect to take 100% equity compensation for remainder of 2022.","Signatera ADLT reimbursement increased to $3,920 per test effective April 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":194133000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372093,"accession_number":"0001104659-22-046150","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2022-04-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Natera director Todd Cozzens resigns from board effective May 25, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Todd Cozzens notified board of resignation on April 8, 2022.","Resignation effective May 25, 2022; no disagreement cited.","No replacement named; departure from board and all committees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390980,"accession_number":"0001104659-22-033098","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2022-03-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Natera executives and board to take stock instead of cash salaries and retainers for 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Executives receive RSUs: CEO Chapman 13,708, CFO Brophy 9,108, COO Schueren 9,634, Sheena 4,141, Rabinowitz 6,763; vest Dec 31, 2022.","All non-employee directors elected RSUs in lieu of quarterly cash retainers for 2022; RSUs vest immediately on issuance.","Compensation change is voluntary, intended to align leadership with shareholders and express confidence in fundamentals.","CEO Steve Chapman says move reflects belief in Natera’s business plan and financial guidance for 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390979,"accession_number":"0001104659-22-026592","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2022-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Natera Q4 revenue $173M (+54% YoY); net loss widens to $140.6M; FY 2022 guidance $770-790M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 revenue $173.0M (+53.9% YoY); full year 2021 revenue $625.5M (+60% YoY), exceeding prior guidance.","Q4 net loss $140.6M ($1.48/share) vs $76.4M loss ($0.89/share) in Q4 2020; FY 2021 net loss $471.7M ($5.21/share).","Processed ~438,800 tests in Q4 (+48.7% YoY); full year ~1,570,000 tests processed.","FY 2022 guidance: revenue $770M-$790M; gross margin ~46%-48%; SG&A $560M-$590M; R&D $340M-$360M; net cash consumption $370M-$400M.","Received CMS coverage for Signatera pan-cancer monitoring; presented positive data from Trifecta and CIRCULATE-Japan studies."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":625486000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409103,"accession_number":"0001104659-21-134389","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2021-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Natera Q3 revenue $158.1M (+61% YoY), net loss $151.3M; raises FY2021 revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $158.1M (+61.1% YoY); product revenue $150.7M (+61.5%); tests processed 407,300 (+55.4%).","Net loss $151.3M (EPS -$1.63) vs loss $58.3M (-$0.72) in Q3 2020; operating loss $150.2M.","Raises 2021 revenue guidance to $615-625M from prior; expects gross margin 49-52%; SG&A $500-520M; R&D $240-260M.","Cash $1.0B; total debt $330.1M ($287.5M convertible notes principal; $50M credit line).","Launched Prospera Kidney/Heart/Lung; exclusive license from Aarhus University for colorectal cancer screening biobank."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":452458000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":428034,"accession_number":"0001104659-21-100755","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2021-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Natera Q2 revenue up 64% to $142M; guides FY2021 revenue to $600-620M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $137.2M, +70.7% YoY; processed 375,700 tests, +60.5%.","Net loss $116.0M ($1.32/share) vs $59.6M ($0.75) a year ago.","Raised 2021 revenue guidance to $600-620M from $550-575M (second increase).","Completed $551.2M net follow-on equity offering in July 2021.","CMS awarded ADLT status for Signatera MRD test; GSK phase III trial announced."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":294342000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":428033,"accession_number":"0001104659-21-094995","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2021-07-22T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Natera prices follow-on offering of 4.5M shares at $113/share, expects ~$478.8M net proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 4,500,000 shares at $113.00 per share; closing expected July 26, 2021.","Underwriters have 30-day option to purchase up to 675,000 additional shares.","Net proceeds estimated at ~$478.8M, or ~$550.7M if option fully exercised.","Joint book-runners: Morgan Stanley, Goldman Sachs, Cowen, SVB Leerink.","Securities offered under automatically effective shelf registration statement filed July 20, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":428032,"accession_number":"0001104659-21-093979","cik":1604821,"company_name":"Natera, Inc.","ticker":"NTRA","form_type":"8-K","filed_at":"2021-07-20T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Natera reports preliminary Q2 revenue ~$138-141M (+60% YoY); Women's Health cash flow breakeven","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue expected $138-141M vs $86.5M in Q2 2020, a record ~60% YoY growth.","Product revenue $135-137M, up ~70% YoY from $80.4M; processed ~370,000 tests (+58%).","Women's Health business achieved cash flow breakeven for the first time in Q2 2021.","Loss from operations widened to $113-117M from $51.7M due to higher R&D and SG&A costs.","On May 11, 2021 entered a development/option deal: paid $10M; option to buy assets for $290M."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":294342000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":29618372373.48205,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}